Kaija-Leena Kolho1, Katri Korpela2, Tytti Jaakkola1, Madharasi V A Pichai3, Erwin G Zoetendal4, Anne Salonen2, Willem M de Vos5. 1. Children's Hospital, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland. 2. Immunobiology Program, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland. 3. Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. 4. Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands. 5. 1] Immunobiology Program, Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland [2] Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands [3] Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
Abstract
OBJECTIVES: Inflammatory bowel disease (IBD) is considered to result from interplay between host and intestinal microbiota. While IBD in adults has shown to be associated with marked changes in the intestinal microbiota, there are only a few studies in children, and particularly studies focusing on therapeutic responses are lacking. Hence, this prospective study addressed the intestinal microbiota in pediatric IBD especially related to the level of inflammation. METHODS: In total, 68 pediatric patients with IBD and 26 controls provided stool and blood samples in a tertiary care hospital and 32 received anti-tumor necrosis factor-α (anti-TNF-α). Blood inflammatory markers and fecal calprotectin levels were determined. The intestinal microbiota was characterized by phylogenetic microarray and qPCR analysis. RESULTS: The microbiota varied along a gradient of increasing intestinal inflammation (indicated by calprotectin levels), which was associated with reduced microbial richness, abundance of butyrate producers, and relative abundance of Gram-positive bacteria (especially Clostridium clusters IV and XIVa). A significant association between microbiota composition and inflammation was indicated by a set of bacterial groups predicting the calprotectin levels (area under curve (AUC) of 0.85). During the induction of anti-TNF-α, the microbial diversity and similarity to the microbiota of controls increased in the responder group by week 6, but not in the non-responders (P<0.01; response related to calprotectin levels). The abundance of six groups of bacteria including those related to Eubacterium rectale and Bifidobacterium spp. predicted the response to anti-TNF-α medication. CONCLUSIONS: Intestinal microbiota represents a potential biomarker for correlating the level of inflammation and therapeutic responses to be further validated.
OBJECTIVES:Inflammatory bowel disease (IBD) is considered to result from interplay between host and intestinal microbiota. While IBD in adults has shown to be associated with marked changes in the intestinal microbiota, there are only a few studies in children, and particularly studies focusing on therapeutic responses are lacking. Hence, this prospective study addressed the intestinal microbiota in pediatric IBD especially related to the level of inflammation. METHODS: In total, 68 pediatric patients with IBD and 26 controls provided stool and blood samples in a tertiary care hospital and 32 received anti-tumor necrosis factor-α (anti-TNF-α). Blood inflammatory markers and fecal calprotectin levels were determined. The intestinal microbiota was characterized by phylogenetic microarray and qPCR analysis. RESULTS: The microbiota varied along a gradient of increasing intestinal inflammation (indicated by calprotectin levels), which was associated with reduced microbial richness, abundance of butyrate producers, and relative abundance of Gram-positive bacteria (especially Clostridium clusters IV and XIVa). A significant association between microbiota composition and inflammation was indicated by a set of bacterial groups predicting the calprotectin levels (area under curve (AUC) of 0.85). During the induction of anti-TNF-α, the microbial diversity and similarity to the microbiota of controls increased in the responder group by week 6, but not in the non-responders (P<0.01; response related to calprotectin levels). The abundance of six groups of bacteria including those related to Eubacterium rectale and Bifidobacterium spp. predicted the response to anti-TNF-α medication. CONCLUSIONS: Intestinal microbiota represents a potential biomarker for correlating the level of inflammation and therapeutic responses to be further validated.
Authors: Chin Wen Png; Sara K Lindén; Kristen S Gilshenan; Erwin G Zoetendal; Chris S McSweeney; Lindsay I Sly; Michael A McGuckin; Timothy H J Florin Journal: Am J Gastroenterol Date: 2010-07-20 Impact factor: 10.864
Authors: Kathleen Machiels; Marie Joossens; João Sabino; Vicky De Preter; Ingrid Arijs; Venessa Eeckhaut; Vera Ballet; Karolien Claes; Filip Van Immerseel; Kristin Verbeke; Marc Ferrante; Jan Verhaegen; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2013-09-10 Impact factor: 23.059
Authors: Ben P Willing; Johan Dicksved; Jonas Halfvarson; Anders F Andersson; Marianna Lucio; Zongli Zheng; Gunnar Järnerot; Curt Tysk; Janet K Jansson; Lars Engstrand Journal: Gastroenterology Date: 2010-10-08 Impact factor: 22.682
Authors: Elena Biagi; Lotta Nylund; Marco Candela; Rita Ostan; Laura Bucci; Elisa Pini; Janne Nikkïla; Daniela Monti; Reetta Satokari; Claudio Franceschi; Patrizia Brigidi; Willem De Vos Journal: PLoS One Date: 2010-05-17 Impact factor: 3.240
Authors: Richard B Gearry; Ann K Richardson; Christopher M Frampton; Andrew J Dodgshun; Murray L Barclay Journal: J Gastroenterol Hepatol Date: 2010-01-14 Impact factor: 4.029
Authors: Katri Korpela; Harry J Flint; Alexandra M Johnstone; Jenni Lappi; Kaisa Poutanen; Evelyne Dewulf; Nathalie Delzenne; Willem M de Vos; Anne Salonen Journal: PLoS One Date: 2014-03-06 Impact factor: 3.240
Authors: D Zama; E Biagi; R Masetti; P Gasperini; A Prete; M Candela; P Brigidi; A Pession Journal: Bone Marrow Transplant Date: 2016-06-27 Impact factor: 5.483
Authors: Phyllissa Schmiedlin-Ren; Laura J Reingold; Christopher S Broxson; Ahren C Rittershaus; Josh S Brudi; Jeremy Adler; Scott R Owens; Ellen M Zimmermann Journal: Am J Physiol Gastrointest Liver Physiol Date: 2016-08-25 Impact factor: 4.052